Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) Announces Earnings Results

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) issued its quarterly earnings results on Monday. The company reported ($0.39) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.06, FiscalAI reports.

Damora Therapeutics, Inc. Common Stock Trading Down 1.3%

NASDAQ:DMRA traded down $0.38 during trading hours on Monday, hitting $29.54. The company had a trading volume of 216,183 shares, compared to its average volume of 388,455. Damora Therapeutics, Inc. Common Stock has a 1 year low of $2.45 and a 1 year high of $38.33. The company has a market cap of $1.82 billion, a P/E ratio of -5.29 and a beta of 1.47. The company has a 50-day moving average of $26.46 and a 200 day moving average of $26.28.

Wall Street Analyst Weigh In

A number of analysts have recently commented on the stock. Royal Bank Of Canada initiated coverage on shares of Damora Therapeutics, Inc. Common Stock in a research note on Friday, April 24th. They set an “outperform” rating and a $40.00 target price for the company. HC Wainwright reiterated a “buy” rating and issued a $45.00 price objective on shares of Damora Therapeutics, Inc. Common Stock in a report on Tuesday, July 21st. Wedbush increased their price objective on Damora Therapeutics, Inc. Common Stock from $35.00 to $40.00 and gave the company an “outperform” rating in a research note on Thursday, July 30th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Damora Therapeutics, Inc. Common Stock in a report on Thursday, June 18th. Finally, TD Cowen began coverage on shares of Damora Therapeutics, Inc. Common Stock in a research report on Monday, June 8th. They issued a “buy” rating for the company. Two research analysts have rated the stock with a Strong Buy rating, eight have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $44.00.

Institutional Investors Weigh In On Damora Therapeutics, Inc. Common Stock

A number of hedge funds have recently modified their holdings of the company. Ikarian Capital LLC acquired a new stake in Damora Therapeutics, Inc. Common Stock during the fourth quarter worth about $6,574,000. Janus Henderson Group PLC purchased a new stake in shares of Damora Therapeutics, Inc. Common Stock in the 4th quarter valued at approximately $40,000. Boothbay Fund Management LLC acquired a new stake in shares of Damora Therapeutics, Inc. Common Stock during the 4th quarter worth approximately $2,204,000. Jain Global LLC acquired a new stake in shares of Damora Therapeutics, Inc. Common Stock during the 4th quarter worth approximately $2,774,000. Finally, Remedium Capital Partners LLC purchased a new stake in shares of Damora Therapeutics, Inc. Common Stock during the 4th quarter valued at approximately $2,772,000. Hedge funds and other institutional investors own 14.20% of the company’s stock.

Damora Therapeutics, Inc. Common Stock Company Profile

Galecto Inc is a clinical‐stage biotechnology company developing small‐molecule therapies that target key pathways involved in fibrotic and malignant diseases. The company’s research focuses on inhibiting galectin‐3, an extracellular carbohydrate‐binding protein implicated in inflammation, fibrosis and tumor progression, as well as lysyl oxidase‐like 2 (LOXL2), an enzyme that crosslinks collagen and elastin in fibrotic tissue.

Its lead programs include GB0139, an inhaled galectin‐3 inhibitor in Phase II trials for idiopathic pulmonary fibrosis and other fibrosing lung diseases, and GB1211, an oral galectin‐3 inhibitor being evaluated for systemic fibrotic disorders.